Cited by 211Hemoglobinopathies and Related DisordersBlood groups and transfusionPlatelet Disorders and Treatments

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid use

Open access

Telen, Marilyn J., Wun, Ted, McCavit, Timothy L., De Castro, Laura M., Krishnamurti, Lakshmanan, Lanzkron, Sophie, Hsu, Lewis L., Smith, Wally R., Rhee, Seungshin, Magnani, John L., Thackray, Helen·2015·Blood

DOI 10.1182/blood-2014-06-583351PMC PMC4408290

Open this paper in CoChat — free account Open PDF

Abstract

Key Points: GMI-1070 led to statistically insignificant but large reductions in time to resolution of VOC and a significant reduction in opioid use. These results support a role for selectins in VOC and progression to a phase 3 study of GMI-1070 for SCD patients with vaso-occlusion.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1182/blood-2014-06-583351

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Causes and Outcomes of the Acute Chest Syndrome in Sickle Cell Disease
Vichinsky, E. P., Neumayr, L. D., Earles, A. N., Williams, R., Lennette, E. T., Dean, D., Nickerson, B., Orringer, E., McKie, V., Bellevue, R., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006223422502 · Cited by 1,234
Population Estimates of Sickle Cell Disease in the U.S.
Hassell, K. L. (2010) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2009.12.022 · Cited by 1,214
Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates
Piel, F. B., Patil, A. P., Howes, R. E., Nyangiri, O. A., Gething, P. W., Dewi, M., Temperley, W. H., Williams, T. N., Weatherall, D. J., & Hay, S. I. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61229-x · Cited by 1,196
The minimum clinically significant difference in visual analogue scale pain score does not differ with severity of pain
Kelly, A.-M. (2001) · Emergency Medicine Journal · doi:10.1136/emj.18.3.205 · Cited by 969
Effect of Hydroxyurea on Mortality and Morbidity in Adult Sickle Cell Anemia
Steinberg, M. H., Barton, F. B., Castro, O. L., Pegelow, C. H., Ballas, S. K., Kutlar, A., Orringer, E. P., Bellevue, R., Olivieri, N. F., Eckman, J. R., et al. (2003) · JAMA · doi:10.1001/jama.289.13.1645 · Cited by 928
Self-citation
The inherited diseases of hemoglobin are an emerging global health burden
Weatherall, D. J. (2010) · Blood · doi:10.1182/blood-2010-01-251348 · Cited by 908
Acute Care Utilization and Rehospitalizations for Sickle Cell Disease
Brousseau, D. C. (2010) · JAMA · doi:10.1001/jama.2010.378 · Cited by 636
Primary role for adherent leukocytes in sickle cell vascular occlusion: A new paradigm
Turhan, A., Weiss, L. A., Mohandas, N., Coller, B. S., & Frenette, P. S. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.052522799 · Cited by 487
Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies
Manwani, D., & Frenette, P. S. (2013) · Blood · doi:10.1182/blood-2013-05-498311 · Cited by 428
The cost of health care for children and adults with sickle cell disease
Kauf, T. L., Coates, T. D., Liu, H., Mody‐Patel, N., & Hartzema, A. G. (2009) · American Journal of Hematology · doi:10.1002/ajh.21408 · Cited by 388

Show all 34 references

Sorted by citations

Biological roles of glycans
Varki, A. (2017) · Glycobiology · doi:10.1093/glycob/cww086 · Cited by 2,635
“The effectiveness of the pan-selectin inhibitor GMI-1070 in reducing selectin-mediated cell adhesion and abrogating crisis shows much promise in early clinical trials (922, 929).”
Background
Sickle-cell disease
Rees, D. C., Williams, T. N., & Gladwin, M. T. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61029-x · Cited by 2,504
Sickle cell disease
Kato, G. J., Piel, F. B., Reid, C. D., Gaston, M. H., Ohene-Frempong, K., Krishnamurti, L., Smith, W. R., Panepinto, J. A., Weatherall, D. J., Costa, F. F., et al. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.10 · Cited by 1,501
Self-citation
Sickle cell disease
Ware, R. E., de Montalembert, M., Tshilolo, L. M., & Abboud, M. R. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30193-9 · Cited by 1,036
Neutrophils as emerging therapeutic targets
Németh, T., Sperandio, M., & Mócsai, A. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0054-z · Cited by 676
Selectins: initiators of leucocyte adhesion and signalling at the vascular wall
McEver, R. P. (2015) · Cardiovascular Research · doi:10.1093/cvr/cvv154 · Cited by 575
Glycosylation in the Era of Cancer-Targeted Therapy: Where Are We Heading?
Mereiter, S., Balmaña, M., Campos, D., Gomes, J., & Reis, C. A. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.06.006 · Cited by 564
Sickle Cell Disease
Kavanagh, P. L., Fasipe, T., & Wun, T. (2022) · JAMA · doi:10.1001/jama.2022.10233 · Cited by 522
Self-citation
The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans
Smith, B. A. H., & Bertozzi, C. R. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00093-1 · Cited by 511
Neutrophils, platelets, and inflammatory pathways at the nexus of sickle cell disease pathophysiology
Zhang, D., Xu, C., Manwani, D., & Frenette, P. S. (2016) · Blood · doi:10.1182/blood-2015-09-618538 · Cited by 413
Intestinal epithelial glycosylation in homeostasis and gut microbiota interactions in IBD
Kudelka, M. R., Stowell, S. R., Cummings, R. D., & Neish, A. S. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0331-7 · Cited by 367
Inflammation in sickle cell disease
Conran, N., & Belcher, J. D. (2018) · Clinical Hemorheology and Microcirculation · doi:10.3233/ch-189012 · Cited by 316
Targeting Glycosylation: A New Road for Cancer Drug Discovery
Costa, A. F., Campos, D., Reis, C. A., & Gomes, C. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.04.002 · Cited by 261
The vaso‐occlusive pain crisis in sickle cell disease: Definition, pathophysiology, and management
Darbari, D. S., Sheehan, V., & Ballas, S. K. (2020) · European Journal Of Haematology · doi:10.1111/ejh.13430 · Cited by 256
Unmasking Fucosylation: from Cell Adhesion to Immune System Regulation and Diseases
Li, J., Hsu, H.-C., Mountz, J. D., & Allen, J. G. (2018) · Cell Chemical Biology · doi:10.1016/j.chembiol.2018.02.005 · Cited by 256
Treating sickle cell disease by targeting HbS polymerization
Eaton, W. A., & Bunn, H. F. (2017) · Blood · doi:10.1182/blood-2017-02-765891 · Cited by 255
Recent insights into structures and functions of C-type lectins in the immune system
Drickamer, K., & Taylor, M. E. (2015) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2015.06.003 · Cited by 250
GBT 440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half‐life in a murine model of sickle cell disease
Oksenberg, D., Dufu, K., Patel, M. P., Chuang, C.-Y., Li, Z., Xu, Q. R., Silva‐Garcia, A., Zhou, C., Hutchaleelaha, A., Patskovska, L. N., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.14214 · Cited by 244
Hydroxyl Groups in Synthetic and Natural-Product-Derived Therapeutics: A Perspective on a Common Functional Group
Cramer, J., Sager, C. P., & Ernst, B. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00179 · Cited by 249
Glycosaminoglycans and Glycosaminoglycan Mimetics in Cancer and Inflammation
Morla, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20081963 · Cited by 214
Recent Advances in the Treatment of Sickle Cell Disease
Cisneros, G. S., & Thein, S. L. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00435 · Cited by 210
Intravascular hemolysis activates complement via cell-free heme and heme-loaded microvesicles
Merle, N. S., Grünenwald, A., Rajaratnam, H., Gnemmi, V., Frimat, M., Figueres, L., Knockaert, S., Bouzekri, S., Charue, D., Noé, R., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.96910 · Cited by 194
The role of neutrophils in thrombosis
Kapoor, S., Opneja, A., & Nayak, L. V. (2018) · Thrombosis Research · doi:10.1016/j.thromres.2018.08.005 · Cited by 199
Therapeutic strategies for sickle cell disease: towards a multi-agent approach
Telen, M. J., Malik, P., & Vercellotti, G. M. (2018) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0003-2 · Cited by 188
Self-citation
Crises in Sickle Cell Disease
Novelli, E. M., & Gladwin, M. T. (2015) · CHEST Journal · doi:10.1016/j.chest.2015.12.016 · Cited by 166
Sickle Cell Anemia and Its Phenotypes
Williams, T. N., & Thein, S. L. (2018) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-083117-021320 · Cited by 165
“Stuck on sugars – how carbohydrates regulate cell adhesion, recognition, and signaling”
Cummings, R. D. (2019) · Glycoconjugate Journal · doi:10.1007/s10719-019-09876-0 · Cited by 149
Glycobiology simplified: diverse roles of glycan recognition in inflammation
Schnaar, R. L. (2016) · Journal of Leukocyte Biology · doi:10.1189/jlb.3ri0116-021r · Cited by 146
Lung vaso-occlusion in sickle cell disease mediated by arteriolar neutrophil-platelet microemboli
Bennewitz, M. F., Jimenez, M. A., Vats, R., Tutuncuoglu, E., Jonassaint, J., Kato, G. J., Gladwin, M. T., & Sundd, P. (2017) · JCI Insight · doi:10.1172/jci.insight.89761 · Cited by 139
Glycomimetics for the inhibition and modulation of lectins
Leusmann, S., Ménová, P., Shanina, E., Titz, A., & Rademacher, C. (2023) · Chemical Society Reviews · doi:10.1039/d2cs00954d · Cited by 136
Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease
Telen, M. J. (2016) · Blood · doi:10.1182/blood-2015-09-618553 · Cited by 134
Self-citation
The Gut Microbiome Regulates Psychological-Stress-Induced Inflammation
Xu, C., Lee, S. K., Zhang, D., & Frenette, P. S. (2020) · Immunity · doi:10.1016/j.immuni.2020.06.025 · Cited by 135
Strategies for the Development of Glycomimetic Drug Candidates
Hevey, R. (2019) · Pharmaceuticals · doi:10.3390/ph12020055 · Cited by 130
Microvascular thrombosis: experimental and clinical implications
Bray, M. A., Sartain, S. E., Gollamudi, J., & Rumbaut, R. E. (2020) · Translational research · doi:10.1016/j.trsl.2020.05.006 · Cited by 126
Heparin Mimetics: Their Therapeutic Potential
Mohamed, S., & Coombe, D. R. (2017) · Pharmaceuticals · doi:10.3390/ph10040078 · Cited by 112
Advances in the Treatment of Sickle Cell Disease
Kapoor, S., Little, J. A., & Pecker, L. H. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2018.08.001 · Cited by 110
Sickle cell disease: Clinical presentation and management of a global health challenge
Houwing, M. E., de Pagter, P. J., van Beers, E. J., Biemond, B. J., Rettenbacher, E., Rijneveld, A. W., Schols, E. M., Philipsen, J. N. J., Tamminga, R. Y. J., van Draat, K. F., et al. (2019) · Blood Reviews · doi:10.1016/j.blre.2019.05.004 · Cited by 106
Selectin catch-bonds mechanotransduce integrin activation and neutrophil arrest on inflamed endothelium under shear flow
Morikis, V. A., Chase, S., Wun, T., Chaikof, E. L., Magnani, J. L., & Simon, S. I. (2017) · Blood · doi:10.1182/blood-2017-05-783027 · Cited by 98
Self-citation
Emerging disease-modifying therapies for sickle cell disease
Carden, M. A., & Little, J. A. (2019) · Haematologica · doi:10.3324/haematol.2018.207357 · Cited by 100
Vaso-occlusive crisis in sickle cell disease: a vicious cycle of secondary events
Jang, T., Poplawska, M., Cimpeanu, E., Mo, G., Dutta, D., & Lim, S. H. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-03074-z · Cited by 105
Therapeutic Targeting of Siglecs using Antibody- and Glycan-Based Approaches
Angata, T., Nycholat, C. M., & Macauley, M. S. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.06.008 · Cited by 100
Selectins—The Two Dr. Jekyll and Mr. Hyde Faces of Adhesion Molecules—A Review
Tvaroška, I., Selvaraj, C., & Koča, J. (2020) · Molecules · doi:10.3390/molecules25122835 · Cited by 98
Selectins and Immune Cells in Acute Myocardial Infarction and Post-infarction Ventricular Remodeling: Pathophysiology and Novel Treatments
Weil, B. R., & Neelamegham, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00300 · Cited by 88
Sialic acid and biology of life: An introduction
Ghosh, S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-816126-5.00001-9 · Cited by 88
Sickle Cell Disease
Azar, S., & Wong, T. E. (2016) · Medical Clinics of North America · doi:10.1016/j.mcna.2016.09.009 · Cited by 86
End points for sickle cell disease clinical trials: patient-reported outcomes, pain, and the brain
Farrell, A. T., Panepinto, J. A., Carroll, C. P., Darbari, D. S., Desai, A. A., King, A. A., Adams, R. J., Barber, T. D., Brandow, A. M., DeBaun, M. R., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000882 · Cited by 84
Ischemia-Reperfusion Injury in Sickle Cell Disease
Ansari, J., & Gavins, F. N. E. (2019) · American Journal Of Pathology · doi:10.1016/j.ajpath.2018.12.012 · Cited by 81
Covalent Lectin Inhibition and Application in Bacterial Biofilm Imaging
Wagner, S., Hauck, D., Hoffmann, M., Sommer, R., Joachim, I., Müller, R., Imberty, A., Varrot, A., & Titz, A. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201709368 · Cited by 77
Sickle cell disease biochip: a functional red blood cell adhesion assay for monitoring sickle cell disease
Alapan, Y., Kim, C., Adhikari, A., Gray, K. E., Gürkan-Çavusoglu, E., Little, J. A., & Gurkan, U. A. (2016) · Translational research · doi:10.1016/j.trsl.2016.03.008 · Cited by 77
Endothelial cells, neutrophils and platelets: getting to the bottom of an inflammatory triangle
Dehghani, T., & Panitch, A. (2020) · Open Biology · doi:10.1098/rsob.200161 · Cited by 77
Innate immune cells, major protagonists of sickle cell disease pathophysiology
Allali, S., Maciel, T. T., Hermine, O., & de Montalembert, M. (2020) · Haematologica · doi:10.3324/haematol.2019.229989 · Cited by 79
Mammalian sugar‐binding receptors: known functions and unexplored roles
Taylor, M. E., & Drickamer, K. (2019) · FEBS Journal · doi:10.1111/febs.14759 · Cited by 68
Emerging point-of-care technologies for sickle cell disease screening and monitoring
Alapan, Y., Fraiwan, A., Kucukal, E., Hasan, M. N., Ung, R., Kim, M., Odame, I., Little, J. A., & Gurkan, U. A. (2016) · Expert Review of Medical Devices · doi:10.1080/17434440.2016.1254038 · Cited by 66
Pediatric sickle cell disease: past successes and future challenges
Meier, E. R., & Rampersad, A. G. (2016) · Pediatric Research · doi:10.1038/pr.2016.204 · Cited by 59
A PSGL-1 glycomimetic reduces thrombus burden without affecting hemostasis
Wong, D. J., Park, D., Park, S. J., Haller, C. A., Chen, J., Dai, E., Liu, L., Mandhapati, A. R., Eradi, P., Dhakal, B., et al. (2021) · Blood · doi:10.1182/blood.2020009428 · Cited by 53
Sevuparin binds to multiple adhesive ligands and reduces sickle red blood cell‐induced vaso‐occlusion
Telen, M. J., Batchvarova, M., Shan, S., Bovée‐Geurts, P. H. M., Zennadi, R., Leitgeb, A. M., Brock, R. E., & Lindgren, M. (2016) · British Journal of Haematology · doi:10.1111/bjh.14303 · Cited by 53
Self-citation
THE EVOLVING PHARMACOTHERAPEUTIC LANDSCAPE FOR THE TREATMENT OF SICKLE CELL DISEASE
Ballas, S. K. (2020) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2020.010 · Cited by 52
How I treat the older adult with sickle cell disease
Thein, S. L., & Howard, J. (2018) · Blood · doi:10.1182/blood-2018-03-818161 · Cited by 53
2015 Clinical trials update in sickle cell anemia
Archer, N. M., Galactéros, F., & Brugnara, C. (2015) · American Journal of Hematology · doi:10.1002/ajh.24116 · Cited by 49
Patrolling monocytes scavenge endothelial-adherent sickle RBCs: a novel mechanism of inhibition of vaso-occlusion in SCD
Liu, Y., Zhong, H., Bao, W., Mendelson, A., An, X., Shi, P. A., Chou, S. T., Manwani, D. G., & Yazdanbakhsh, K. (2019) · Blood · doi:10.1182/blood.2019000172 · Cited by 51
Immunomodulatory Therapy of Inflammatory Liver Disease Using Selectin-Binding Glycopolymers
Bartneck, M., Schlößer, C. T., Barz, M., Zentel, R., Trautwein, C., Lammers, T., & Tacke, F. (2017) · ACS Nano · doi:10.1021/acsnano.7b04630 · Cited by 47
Factor H interferes with the adhesion of sickle red cells to vascular endothelium: a novel disease-modulating molecule
Lombardi, E., Mattè, A., Risitano, A. M., Ricklin, D., Lambris, J. D., Zanet, D. D., Jokiranta, S. T., Martinelli, N., Scambi, C., Salvagno, G. L., et al. (2019) · Haematologica · doi:10.3324/haematol.2018.198622 · Cited by 45
A randomized clinical trial of the efficacy and safety of rivipansel for sickle cell vaso-occlusive crisis
Dampier, C., Telen, M. J., Wun, T., Brown, C., Desai, P. C., Rassi, F. A. E., Fuh, B., Kanter, J., Pastore, Y. D., Rothman, J., et al. (2022) · Blood · doi:10.1182/blood.2022015797 · Cited by 45
Self-citation
Targeting P-selectin glycoprotein ligand-1/P-selectin interactions as a novel therapy for metabolic syndrome
Patel, M. S., Miranda-Nieves, D., Chen, J., Haller, C. A., & Chaikof, E. L. (2016) · Translational research · doi:10.1016/j.trsl.2016.11.007 · Cited by 46
Measuring success: utility of biomarkers in sickle cell disease clinical trials and care
Kalpatthi, R. V., & Novelli, E. M. (2018) · Hematology · doi:10.1182/asheducation-2018.1.482 · Cited by 47
Sickle Cell Disease Update: New Treatments and Challenging Nutritional Interventions
Bell, V., Varzakas, T. H., Ψαλτοπούλου, Θ., & Fernandes, T. H. (2024) · Nutrients · doi:10.3390/nu16020258 · Cited by 44
Drug Therapies for the Management of Sickle Cell Disease
Rai, P., & Ataga, K. I. (2020) · F1000Research · doi:10.12688/f1000research.22433.1 · Cited by 43
Neutrophil Mechanosignaling Promotes Integrin Engagement With Endothelial Cells and Motility Within Inflamed Vessels
Morikis, V. A., & Simon, S. I. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02774 · Cited by 46
NEW THERAPEUTIC OPTIONS FOR THE TREATMENT OF SICKLE CELL DISEASE
Mattè, A., Mazzi, F., Federti, E., Olivieri, O., & Franceschi, L. D. (2019) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2019.002 · Cited by 46
Emerging therapies in sickle cell disease
Nardo‐Marino, A., Brousse, V. A. M., & Rees, D. C. (2020) · British Journal of Haematology · doi:10.1111/bjh.16504 · Cited by 42
P-Selectin Blockade in the Treatment of Painful Vaso-Occlusive Crises in Sickle Cell Disease: A Spotlight on Crizanlizumab
Karki, N. R., & Kutlar, A. (2021) · Journal of Pain Research · doi:10.2147/jpr.s278285 · Cited by 43
Targeting the P-selectin/PSGL-1 pathway: discovery of disease-modifying therapeutics for disorders of thromboinflammation
Escopy, S., & Chaikof, E. L. (2024) · Blood Vessels Thrombosis & Hemostasis · doi:10.1016/j.bvth.2024.100015 · Cited by 39
An Analysis of Trafficking Receptors Shows that CD44 and P-Selectin Glycoprotein Ligand-1 Collectively Control the Migration of Activated Human T-Cells
Ali, A. J., Abuelela, A. F., & Merzaban, J. S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00492 · Cited by 39
Pathophysiology and recent therapeutic insights of sickle cell disease
Shah, F., & Dwivedi, M. (2020) · Annals of Hematology · doi:10.1007/s00277-020-03977-9 · Cited by 36
Pain in sickle cell disease: current and potential translational therapies
Sagi, V., Mittal, A., Tran, H., & Gupta, K. (2021) · Translational research · doi:10.1016/j.trsl.2021.03.007 · Cited by 38
Pain and sickle cell disease
Aich, A., Jones, M. K., & Gupta, K. (2019) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000491 · Cited by 37
Sevuparin for the treatment of acute pain crisis in patients with sickle cell disease: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Biemond, B. J., Tombak, A., Kılınç, Y., Al-Khabori, M. K., Abboud, M. R., Nafea, M., Inati, A. C., Wali, Y. A. M. S., Kristensen, J. H., Kowalski, J. H., et al. (2021) · The Lancet Haematology · doi:10.1016/s2352-3026(21)00053-3 · Cited by 37
PF ‐04447943, a Phosphodiesterase 9A Inhibitor, in Stable Sickle Cell Disease Patients: A Phase Ib Randomized, Placebo‐Controlled Study
Charnigo, R. J., Beidler, D. R., Rybin, D. V., Pittman, D. D., Tan, B., Howard, J., Michelson, A. D., Frelinger, A. L., & Clarke, N. P. (2018) · Clinical and Translational Science · doi:10.1111/cts.12604 · Cited by 36
New insights into sickle cell disease
Kato, G. J. (2016) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000241 · Cited by 37
Novel insights in the management of sickle cell disease in childhood
Iughetti, L. (2016) · World Journal of Clinical Pediatrics · doi:10.5409/wjcp.v5.i1.25 · Cited by 35
New insights into the pathophysiology and development of novel therapies for sickle cell disease
Moerdler, S., & Manwani, D. G. (2018) · Hematology · doi:10.1182/asheducation-2018.1.493 · Cited by 35
Vasculopathy in Sickle Cell Disease: From Red Blood Cell Sickling to Vascular Dysfunction
Nader, É., Conran, N., Romana, M., & Connes, P. (2021) · Comprehensive physiology · doi:10.1002/cphy.c200024 · Cited by 35
Harnessing cancer cell metabolism for theranostic applications using metabolic glycoengineering of sialic acid in breast cancer as a pioneering example
Badr, H. A., AlSadek, D. M. M., El-Houseini, M. E., Saeui, C. T., Mathew, M. P., Yarema, K. J., & Ahmed, H. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.11.044 · Cited by 34
Emerging pharmacotherapeutic approaches for the management of sickle cell disease
Torres, L. S., & Conran, N. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1548610 · Cited by 34
The trials and hopes for drug development in sickle cell disease
Ataga, K. I., & Stocker, J. W. (2015) · British Journal of Haematology · doi:10.1111/bjh.13548 · Cited by 32
ARQ 092, an orally-available, selective AKT inhibitor, attenuates neutrophil-platelet interactions in sickle cell disease
Kim, K., Li, J., Barazia, A., Tseng, A., Youn, S., Abbadessa, G., Yu, Y., Schwartz, B. E., Andrews, R. K., Gordeuk, V. R., et al. (2016) · Haematologica · doi:10.3324/haematol.2016.151159 · Cited by 32
Pharmacological interventions for painful sickle cell vaso-occlusive crises in adults
Cooper, T. E., Hambleton, I. R., Ballas, S. K., Cashmore, B. A., & Wiffen, P. J. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012187.pub2 · Cited by 29
Sickle cell vaso-occlusion: The dialectic between red cells and white cells
Conran, N., & Embury, S. H. (2021) · Experimental Biology and Medicine · doi:10.1177/15353702211005392 · Cited by 31
VLA ‐4 blockade by natalizumab inhibits sickle reticulocyte and leucocyte adhesion during simulated blood flow
White, J. U., Krishnamoorthy, S., Gupta, D., Lancelot, M. M., Moore, N., Sarnaik, S. A., Hobbs, W. E., Light, D. R., & Hines, P. C. (2016) · British Journal of Haematology · doi:10.1111/bjh.14158 · Cited by 29
Systematic Review of Crizanlizumab: A New Parenteral Option to Reduce Vaso‐occlusive Pain Crises in Patients with Sickle Cell Disease
Han, J., Saraf, S. L., & Gordeuk, V. R. (2020) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2409 · Cited by 29
State of the Art Management of Acute Vaso-occlusive Pain in Sickle Cell Disease
Puri, L., Nottage, K. A., Hankins, J. S., & Anghelescu, D. L. (2017) · Pediatric Drugs · doi:10.1007/s40272-017-0263-z · Cited by 28
Sickle cell disease as a vascular disorder
Ofori-Acquah, S. F. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2020.1758555 · Cited by 28
Microfluidics in Sickle Cell Disease Research: State of the Art and a Perspective Beyond the Flow Problem
Aich, A., Lamarre, Y., Sacomani, D. P., Kashima, S. H., Covas, D. T., & de la Torre, L. G. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.558982 · Cited by 27
Selectin-mediated leukocyte trafficking during the development of autoimmune disease
Angiari, S. (2015) · Autoimmunity Reviews · doi:10.1016/j.autrev.2015.06.006 · Cited by 29
Improved health care utilization and costs in transplanted versus non-transplanted adults with sickle cell disease
Saraf, S. L., Ghimire, K. B., Patel, P. R., Sweiss, K. I., Gowhari, M., Molokie, R. E., Gordeuk, V. R., & Rondelli, D. (2020) · PLoS ONE · doi:10.1371/journal.pone.0229710 · Cited by 26
Research in Sickle Cell Disease: From Bedside to Bench to Bedside
Cisneros, G. S., & Thein, S. L. (2021) · HemaSphere · doi:10.1097/hs9.0000000000000584 · Cited by 25
Norovirus, glycans and attachment
Taube, S., Mallagaray, Á., & Peters, T. (2018) · Current Opinion in Virology · doi:10.1016/j.coviro.2018.04.007 · Cited by 23
Hydroxyurea with AKT2 inhibition decreases vaso-occlusive events in sickle cell disease mice
Barazia, A., Li, J., Kim, K., Shabrani, N. C., & Cho, J. (2015) · Blood · doi:10.1182/blood-2015-02-626234 · Cited by 23
Sialyl-LewisX Glycoantigen Is Enriched on Cells with Persistent HIV Transcription during Therapy
Colomb, F., Giron, L. B., Kuri-Cervantes, L., Adeniji, O. S., Ma, T., Dweep, H., Battivelli, E., Verdin, E. M., Palmer, C. S., Tateno, H., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107991 · Cited by 22
Optimizing the care model for an uncomplicated acute pain episode in sickle cell disease
Telfer, P. T., & Kaya, B. (2017) · Hematology · doi:10.1182/asheducation-2017.1.525 · Cited by 21

Authors: Telen, M. J., Wun, T., McCavit, T. L., De Castro, L. M., Krishnamurti, L., Lanzkron, S., Hsu, L. L., Smith, W. R., Rhee, S., Magnani, J. L., & Thackray, H.
Affiliations: Duke University (US)
VA Northern California Health Care System (US)
The University of Texas Southwestern Medical Center (US)
Department of Medicine, Division of Hematology and Oncology, University of Pittsburgh, Pittsburgh, PA;
Emory University (US)
Johns Hopkins University (US)
University of Illinois Chicago (US)
Virginia Commonwealth University (US)
Rho (United States) (US)
GlycoMimetics (United States) (US)
ORCID: Telen, Marilyn J.
Wun, Ted
Krishnamurti, Lakshmanan
Lanzkron, Sophie
Hsu, Lewis L.
Smith, Wally R.
Venue: Blood
Publisher: American Society of Hematology
Published: 2015-04-23
Volume: 125
Issue: 17
Pages: 2656-2664
ISSN: 0006-4971 (ISSN-L)
1528-0020
DOI: 10.1182/blood-2014-06-583351
PMC: PMC4408290
OpenAlex: W2077716817
Cited by: 211
References: 34
Citations by year: 2026: 2 · 2025: 11 · 2024: 10 · 2023: 8 · 2022: 10 · 2021: 20 · 2020: 24 · 2019: 36 · 2018: 27 · 2017: 24 · 2016: 24 · 2015: 13
FWCI: 16.41
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Blood (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
eScholarship (California Digital Library) (submittedVersion)
Funders: University of California
Children's Hospital of Philadelphia
University of Miami
Emory University
Cincinnati Children's Hospital Medical Center
Harvard University
Johns Hopkins University
University of Cincinnati
Virginia Commonwealth University
Children's National Hospital
Hospital for Sick Children
University of Illinois at Urbana-Champaign
Leonard M. Miller School of Medicine
University of Colorado Denver
Children's Hospital of Pittsburgh
Topics: Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
Health Sciences › Medicine › Hematology › Blood groups and transfusion
Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
Keywords: sickle cell disease, vaso-occlusive crisis, selectin inhibitors, cell adhesion, opioid analgesic use, time to resolution, drug safety
MeSH terms: Adolescent, Adult, Analgesics, Analgesics, Opioid, Anemia, Sickle Cell, Child, Double-Blind Method, Female, Glycolipids, Humans, Male, Middle Aged, Prospective Studies, Vascular Diseases, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid use

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks